secwatch / observer
8-K filed May 7, 2026, 7:59 PM ET ticker SLN CIK 0001479615
earnings confidence high sentiment neutral materiality 0.50

Silence Therapeutics Q1 net loss $15M; Phase 2 PV trial on track for August 2026 topline

Silence Therapeutics plc

2026-Q1 EPS reported -$0.11 revenue$422,000
item 2.02item 9.01

Machine-readable event card

schema_version
secwatch.filing_event.v1
accession
0001193125-26-210428
form_type
8-K
ticker
SLN
cik
0001479615
company_name
Silence Therapeutics plc
filed_at
2026-05-07T23:59:59+00:00
discovered_at
2026-05-14T18:02:32.343897+00:00
generated_at
2026-05-14T21:35:43.730559+00:00
sec_items
["2.02", "9.01"]
event_type
earnings
sentiment
neutral
materiality_score
0.5
calibrated_materiality_score
0.5
confidence
high
secwatch_canonical_url
https://secwatch.observer/filing/0001193125-26-210428
json_url
https://secwatch.observer/filing/0001193125-26-210428.json
markdown_url
https://secwatch.observer/filing/0001193125-26-210428.md
text_url
https://secwatch.observer/filing/0001193125-26-210428.txt
edgar_index_url
https://www.sec.gov/Archives/edgar/data/1479615/000119312526210428/0001193125-26-210428-index.htm
edgar_primary_document_url
https://www.sec.gov/Archives/edgar/data/1479615/000119312526210428/sln-20260507.htm
generated_by_model
deepseek-v4-flash:cloud@v2
review_status
machine_generated
human_reviewed
false
corrected
false
correction_note
null
correction_timestamp
null
superseded_by
null
JSON Markdown Plain text

Source-grounded claims

b72c2d50ab8cc026011baad4bd52ca7f32d2fa11

Silence Therapeutics plc reported the first quarter ended March 31, 2026 results: revenue $0.4 million, net income Net loss was $15.0 million, or $0.11 basic and diluted net loss per share, EPS $0.11 basic and diluted net loss per share.

cash equivalents of $5.7 million and short-term investments of $64.4 million. • Collaboration Revenue: Collaboration revenue recognized under our agreement with AstraZeneca was $0.4 million for the three months ended March 31, 2026, compared to $0.1 million for the three months ended March 31, 2025. • R&D Expenses: Research and development (R&D) expenses were $9.1

SEC 8-K Item 2.02 confidence 0.9 SEC evidence

Comparable filings

EXPI

eXp World Holdings Q1 revenue $1.0B (+5% YoY), net loss narrows to $(5.1M), Adj. EBITDA $4.1M (+88%)

eXp World Holdings, Inc. May 11, 2026, 7:59 PM ET earnings Items 2.02, 7.01, 9.01

same fact type: earnings_release same SEC item: 2.02, 9.01 same event type: earnings similar materiality

This filing

cash equivalents of $5.7 million and short-term investments of $64.4 million. • Collaboration Revenue: Collaboration revenue recognized under our agreement with AstraZeneca was $0.4 million for the three months ended March 31, 2026, compared to $0.1 million for the three months ended March 31, 2025. • R&D Expenses: Research and development (R&D) expenses were $9.1

Comparable filing

the company's scale and our focus on operational efficiency across eXp World Holdings,” said Jesse Hill, Chief Financial Officer of eXp World Holdings. “We generated revenue of $1.0 billion and Adjusted EBITDA of $4.1 million, an 88% improvement that further strengthened our financial position. More recently, we executed the strategic NextHome acquisition using cash

Filing page SEC filing

HAIN

Hain Celestial reports Q3 FY2026 earnings; detailed figures not included in filing excerpt

HAIN CELESTIAL GROUP INC May 11, 2026, 7:59 PM ET earnings Items 2.02, 9.01

same fact type: earnings_release same SEC item: 2.02, 9.01 same event type: earnings similar materiality

This filing

cash equivalents of $5.7 million and short-term investments of $64.4 million. • Collaboration Revenue: Collaboration revenue recognized under our agreement with AstraZeneca was $0.4 million for the three months ended March 31, 2026, compared to $0.1 million for the three months ended March 31, 2025. • R&D Expenses: Research and development (R&D) expenses were $9.1

Comparable filing

On May 11, 2026, The Hain Celestial Group, Inc. (the “Company”) issued a press release announcing financial results for its third quarter ended March 31, 2026.

Filing page SEC filing

HRTX

Heron Q1 net revenue $34.7M (-10.8% YoY); Acute Care up 32%; guidance reaffirmed

HERON THERAPEUTICS, INC. /DE/ May 11, 2026, 7:59 PM ET earnings Items 2.02, 9.01

same fact type: earnings_release same SEC item: 2.02, 9.01 same event type: earnings similar materiality

This filing

cash equivalents of $5.7 million and short-term investments of $64.4 million. • Collaboration Revenue: Collaboration revenue recognized under our agreement with AstraZeneca was $0.4 million for the three months ended March 31, 2026, compared to $0.1 million for the three months ended March 31, 2025. • R&D Expenses: Research and development (R&D) expenses were $9.1

Comparable filing

Reaffirms Guidance - Q1 2026 net revenue growth year-over year for Acute Care franchise (+32%), including ZYNRELEF ® (+27%) and APONVIE ® (+50%) - Q1 2026 total net revenue of $34.7 million - Reached settlement with Baxter Healthcare Corporation in CINVANTI ® patent litigation - Reaffirmed 2026 full-year guidance of $173–$183 million net revenue; $10–$20 million

Filing page SEC filing

XGN

Exagen Q1 2026: Record revenue $17.3M, net loss $4.0M; FY guidance reaffirmed

EXAGEN INC. May 11, 2026, 7:59 PM ET earnings Items 2.02, 9.01

same fact type: earnings_release same SEC item: 2.02, 9.01 same event type: earnings similar materiality

This filing

cash equivalents of $5.7 million and short-term investments of $64.4 million. • Collaboration Revenue: Collaboration revenue recognized under our agreement with AstraZeneca was $0.4 million for the three months ended March 31, 2026, compared to $0.1 million for the three months ended March 31, 2025. • R&D Expenses: Research and development (R&D) expenses were $9.1

Comparable filing

Trailing-twelve-month average selling price (ASP) $ 444 $ 419 Cash and cash equivalents $ 21,513 $ 11,194 First Quarter 2026 Highlights: • Achieved record total revenue of $17.3 million, an increase of 12% compared to first quarter 2025. • Grew AVISE CTD test volume 10% compared to first quarter 2025. • Expanded AVISE CTD trailing-twelve-month ASP to $444 per

Filing page SEC filing

CGBD

Carlyle Secured Lending Q1 NII $0.36/sh; NAV down 2.3% to $15.89; declares $0.35 dividend

Carlyle Secured Lending, Inc. May 11, 2026, 7:59 PM ET earnings Items 2.02, 7.01, 9.01

same fact type: earnings_release same SEC item: 2.02, 9.01 same event type: earnings similar materiality

This filing

cash equivalents of $5.7 million and short-term investments of $64.4 million. • Collaboration Revenue: Collaboration revenue recognized under our agreement with AstraZeneca was $0.4 million for the three months ended March 31, 2026, compared to $0.1 million for the three months ended March 31, 2025. • R&D Expenses: Research and development (R&D) expenses were $9.1

Comparable filing

For the first quarter of 2026, we reported $0.36 per common share of Net Investment Income and Adjusted Net Investment Income, a non-GAAP financial measure described below.

Filing page SEC filing

OPAL

OPAL Fuels Q1 2026 Adj EBITDA $16.7M, net loss $(5.6)M; revenue down 14% YoY

OPAL Fuels Inc. May 11, 2026, 7:59 PM ET earnings Items 2.02, 9.01

same fact type: earnings_release same SEC item: 2.02, 9.01 same event type: earnings similar materiality

This filing

cash equivalents of $5.7 million and short-term investments of $64.4 million. • Collaboration Revenue: Collaboration revenue recognized under our agreement with AstraZeneca was $0.4 million for the three months ended March 31, 2026, compared to $0.1 million for the three months ended March 31, 2025. • R&D Expenses: Research and development (R&D) expenses were $9.1

Comparable filing

Revenue for the three months ended March 31, 2026 and 2025, was $73.4 million and $85.4 million respectively, a decrease of (14)%, compared to the same period last year. 1 • Net (loss) income for the three months ended March 31, 2026 was $(5.6) million, compared to $1.3 million in the same period last year. • Basic and diluted net loss per share attributable to Class A common shareholders for the three months ended months ended March 31, 2026 were $(0.09) compared to $(0.01) in the comparable period last year.

Filing page SEC filing

OLPX

Olaplex Q1 net sales up 2.5% to $99.4M but swings to net loss of $5.3M; adjusted EBITDA falls 26.1%

OLAPLEX HOLDINGS, INC. May 11, 2026, 7:59 PM ET earnings Items 2.02, 9.01

same fact type: earnings_release same SEC item: 2.02, 9.01 same event type: earnings similar materiality

This filing

cash equivalents of $5.7 million and short-term investments of $64.4 million. • Collaboration Revenue: Collaboration revenue recognized under our agreement with AstraZeneca was $0.4 million for the three months ended March 31, 2026, compared to $0.1 million for the three months ended March 31, 2025. • R&D Expenses: Research and development (R&D) expenses were $9.1

Comparable filing

team for their continued dedication and commitment to our transformation." For the first quarter of 2026 compared to the first quarter of 2025: • Net sal es increased 2.5% to $99.4 million; ◦ By channel: ▪ Specialty Retail decreased 13.3% to $33.4 million; ▪ Professional increased 12.3% to $38.8 million; ▪ Direct-To-Consumer increased 13.8% to $27.2 million; ◦ Net

Filing page SEC filing

FEMY

Femasys reports Q1 net income of $846K; sales up 24.5%; cash sufficient into Q3 2026

FEMASYS INC May 8, 2026, 7:59 PM ET earnings Items 2.02, 9.01

same fact type: earnings_release same SEC item: 2.02, 9.01 same event type: earnings similar materiality

This filing

cash equivalents of $5.7 million and short-term investments of $64.4 million. • Collaboration Revenue: Collaboration revenue recognized under our agreement with AstraZeneca was $0.4 million for the three months ended March 31, 2026, compared to $0.1 million for the three months ended March 31, 2025. • R&D Expenses: Research and development (R&D) expenses were $9.1

Comparable filing

addressing critical unmet needs with safe, technologically advanced products.” Financial Results for Quarter Ended March 31, 2026 • Sales increased by $83,625, or 24.5%, to $424,889 in 2026 from $341,264 in 2025, primarily due to sales of FemBloc. • Research and development expenses decreased by $1,659,071, or 55.9%, to $1,309,401 in 2026 compared to

Filing page SEC filing

Source: SEC EDGAR
accession 0001193125-26-210428
view filing index on sec.gov
view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.